A Phase 2, Randomized, Double Blinded, Placebo Controlled, Parallel Group, Single Administration Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19
Latest Information Update: 06 Mar 2023
At a glance
- Drugs Efineptakin alfa (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Kalbe Farma
- 22 Mar 2021 Status changed from planning to recruiting.
- 01 Jan 2021 New trial record
- 30 Dec 2020 According to a Kalbe media release, it has received approval for a clinical trial (PPUK) from the Food and Drug Administration of the Republic of Indonesia (BPOM) to carry out Phase 2 clinical trials of the drug GX-17, which is an immunotherapeutic drug that will be developed as a treatment for COVID-19 patients.